Murine Immuno-Oncology Models: A Head-to-Head Comparison Between Syngeneics and Tumor Homografts
Presenter: Dr. Toni Jun, Crown Bioscience
Syngeneics have been the mainstay model for surrogate immunotherapy evaluation as an easy-to-establish platform with well characterized driver mutations. Murine homograft models, which are developed from spontaneous tumors and never manipulated to grow in vitro, provide a novel alternative for immunotherapy testing with the presence of a relevant stroma, closer mutational load and tissue architecture to human tumors, and a wider range of available models.
In this webinar Dr. Jun will review the key features of syngeneics and murine tumor homograft models (the MuPrime™ platform). Dr. Jun will present a comparison between these immunocompetent murine models, discussing their strengths and limitations when applied to immunotherapy research.
Watch this webinar to learn how to:
- Choose between syngeneics and MuPrime murine tumor homograft models for immuno-oncology applications
- Take advantage of each model features and work around their limitations
- Utilize these models to predict patient response to immunotherapy
About The Presenter:
Dr. Toni Jun is a Director of Scientific Engagement at Crown Bioscience and has over 17 years of experience in drug discovery experience in both small and large biotech companies. She has extensive experience initiating and leading programs using multiple modalities, including small molecules, antibodies, and bispecific molecules for immuno-oncology, immunology, and oncology programs.
Toni is a graduate of the University of Michigan, Ann Arbor, and received her Ph.D. from Harvard University, Committee on Virology. She has contributed to multiple patents and peer-reviewed publications throughout her career.